ArticleJournal of gastrointestinal oncology2025
A promising model for prediction of chemotherapeutic sensitivity in gastrointestinal cancers using patient-derived malignant ascites organoids.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- [Current status and challenges of artificial intelligence and organoid technologies in precision diagnosis and treatment of gastrointestinal stromal tumors].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Organoids in cancer therapy: translational applications and clinical promise.Molecular cancer · 2026Review
- From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers.Journal of gastrointestinal oncology · 2026Article
- Article
- Advances in organoids for personalized medicine: from technological development to clinical application.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The overall treatment efficacy for gastrointestinal (GI) cancer patients with malignant ascites remains suboptimal. This study aims to construct malignant ascites-derived organoids (MADOs) that simulate the tumor characteristics of patients, thereby enabling personalized prediction of chemotherapeutic sensitivity. Methods: Malignant ascites were collected from patients with GI malignancies for organoid culturing. The consistency between the MADOs and the Results: A total of 32 malignant ascites samples were collected for organoid culturing, with 24 cases successfully established. The MADOs exhibited high consistency with Conclusions: Organoids derived from malignant ascites in GI malignancies have a high culturing success rate and simulate the characteristics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.